SCHEMBL3450301

SCHEMBL3450301

Cc1nccn1-c1nc(Nc2ccc(F)c(Cl)c2)ncc1-c1cncnc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.43
STK17A Q9UEE5 2/20 0.43
KDR P35968 6/20 0.42
APP P05067 2/20 0.41
AXL P30530 3/20 0.41
STK17B O94768 1/20 0.40
EGFR P00533 6/20 0.39
PDGFRB P09619 1/20 0.39
FGFR1 P11362 1/20 0.39
SRC P12931 1/20 0.39
PDGFRA P16234 1/20 0.39
STAT5A P42229 1/20 0.39
ACVR1 Q04771 1/20 0.39
PKMYT1 Q99640 1/20 0.39
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
GRM4 Q14833 1/20 0.37
SYK P43405 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3450305 0.90 MAPK1 (0.48) MAPK1STK17AKDRAPPAXL
SCHEMBL3450773 0.87 CSNK2A1 (0.42) STK17AEGFRABL1BCR
SCHEMBL3448560 0.83 FGFR1 (0.42) STK17AAXLEGFRFGFR1ABL1
SCHEMBL3450615 0.83 MAPK1 (0.46) MAPK1STK17AKDRAPPAXL
SCHEMBL3448245 0.83 MAPK1 (0.47) MAPK1STK17AKDRAPPAXL
SCHEMBL3449347 0.83 MAPK1 (0.47) MAPK1STK17AKDRAPPAXL
SCHEMBL3448295 0.82 MAPK1 (0.45) MAPK1STK17AKDRAPPAXL
SCHEMBL3450699 0.82 KCNN3 (0.51) MAPK1STK17AKDRAPPAXL
SCHEMBL13310864 0.82 MAPK1 (0.44) MAPK1STK17AKDRAPPAXL
SCHEMBL3447505 0.80 MAPK1 (0.49) MAPK1STK17AAPPAXLSTK17B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD MAPK1 2905/4885STK17A 1984/4885KDR 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.